FDA Approves bluebird bio’s ZYNTEGLO®, the First Gene Therapy for People with Transfusion-Dependent Beta-Thalassemia » bluebird_bio_approval

zynteglo_approved_thalassemia

This entry was posted on Wednesday, August 17th, 2022 at 9:41 pm and is filed under . You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.

Secured By miniOrange